Latest Infant Milk Formula News

Australian Dairy Nutritionals Group has cut its net loss by 40% in the half-year to December 2025, driven by a remarkable 431% revenue jump in its nutritional powders segment amid expanding Chinese distribution.

The a2 Milk Company has reported robust half-year results with strong revenue and earnings growth, driven by gains in infant formula and liquid milk segments, alongside a strategic supply chain transformation. The company has upgraded its full-year outlook and announced a substantial special dividend, signalling confidence in its growth trajectory.

The a2 Milk Company has secured key regulatory approvals in China, moving closer to launching its infant formula products under the a2MC brand by mid-2027.

The a2 Milk Company has raised its FY26 revenue guidance, citing stronger-than-expected performance in key product categories and favourable currency movements. The company anticipates solid earnings growth and robust cash flow conversion.

The a2 Milk Company is expanding its strategic partnership with China State Farm to include English label infant milk formula products, starting with a2 Genesis™ in early 2026. This move aims to strengthen distribution control and capitalize on China’s booming infant formula market.

Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.

The a2 Milk Company delivered record FY25 results with $1.9 billion in sales and announced a transformative acquisition of a New Zealand manufacturing facility, alongside divesting its stake in Mataura Valley Milk and planning a $300 million special dividend.

The a2 Milk Company reported a robust 21% rise in net profit for FY25, driven by strong growth in China and the USA, alongside a landmark full-year dividend declaration and major supply chain restructuring.

The a2 Milk Company reported record FY25 results with $1.9 billion in sales and declared its first-ever dividends, while advancing a major supply chain overhaul through a key New Zealand manufacturing acquisition and divestment.

Bubs Australia Limited reports a strong FY25 with 29% revenue growth to $102.5 million, positive EBITDA turnaround, and sustained cash flow improvements. The company also advances its US market ambitions with a key FDA submission underway.

Bubs Australia has submitted critical clinical trial data to the US FDA, marking a pivotal step toward permanent approval for its infant formulas in the US market.

The a2 Milk Company posted robust first-half FY25 results, lifting revenue by 10.1% and net profit by 7.6%, while introducing a dividend policy for the first time. Strong English label IMF sales and liquid milk growth underpin an upgraded full-year outlook.